Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Réa D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Jul 10. pii: clincanres.3373.2018. doi: 10.1158/1078-0432.CCR-18-3373. [Epub ahead of print]

PMID:
31292142
2.

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).

Br J Haematol. 2019 Jul 4. doi: 10.1111/bjh.16083. [Epub ahead of print]

PMID:
31271217
3.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

4.

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P.

Haematologica. 2019 Apr;104(4):e131-e133. doi: 10.3324/haematol.2018.203885. Epub 2018 Oct 31. No abstract available.

5.

Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Richez V, Gruchet C, Guidez S, Fouquet G, Azais I, Durand G, Javaugue V, Brigaud A, Plasse F, Diolez J, Machet A, Moya N, Gardeney H, Franques P, Bobin A, Levy A, Sabirou F, Bonnin A, Dieval C, Primault S, Barrier J, Fleck E, Bouyier S, Daras C, Princet I, Bauwens D, Legros L, Fuzibet JG, Gil A, Bridoux F, Avet-Loiseau H, Leleu X.

Am J Hematol. 2019 Jan;94(1):E17-E20. doi: 10.1002/ajh.25327. Epub 2018 Nov 25. No abstract available.

PMID:
30358902
6.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

7.

The psoas muscle transversal diameter predicts mortality in patients with cirrhosis on a waiting list for liver transplantation: A retrospective cohort study.

Huguet A, Latournerie M, Debry PH, Jezequel C, Legros L, Rayar M, Boudjema K, Guyader D, Jacquet EB, Thibault R.

Nutrition. 2018 Jul - Aug;51-52:73-79. doi: 10.1016/j.nut.2018.01.008. Epub 2018 Feb 9.

8.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

9.

Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis.

Legué C, Legros L, Kammerer-Jacquet S, Jézequel C, Houssel-Debry P, Uguen T, Le Lan C, Guillygomarc'h A, Moirand R, Turlin B, Guyader D, Bardou-Jacquet E.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):290-291. doi: 10.1016/j.cgh.2017.07.032. Epub 2017 Aug 3. No abstract available.

10.

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.

PMID:
28772207
11.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.

12.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

13.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R.

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. No abstract available.

14.

Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides.

Goulois J, Lambert V, Legros L, Benoit E, Lattard V.

Ecol Evol. 2017 Mar 21;7(8):2767-2776. doi: 10.1002/ece3.2829. eCollection 2017 Apr.

15.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
16.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

17.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

18.

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M.

Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.

19.

Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension.

Legros L, Chabanne C, Camus C, Fournet M, Houssel-Debry P, Latournerie M, Jezequel C, Rayar M, Boudjema K, Guyader D, Bardou-Jacquet E.

Dig Liver Dis. 2017 Mar;49(3):301-307. doi: 10.1016/j.dld.2016.10.010. Epub 2016 Oct 26.

PMID:
27840058
20.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.

21.

Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease.

Kiani A, Brun V, Lainé F, Turlin B, Morcet J, Michalak S, Le Gruyer A, Legros L, Bardou-Jacquet E, Gandon Y, Moirand R.

World J Gastroenterol. 2016 May 28;22(20):4926-35. doi: 10.3748/wjg.v22.i20.4926.

22.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

23.

Study of the efficiency of anticoagulant rodenticides to control Mus musculus domesticus introgressed with Mus spretus Vkorc1.

Goulois J, Hascoët C, Dorani K, Besse S, Legros L, Benoit E, Lattard V.

Pest Manag Sci. 2017 Feb;73(2):325-331. doi: 10.1002/ps.4319. Epub 2016 Jun 23.

PMID:
27196872
24.

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.

Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG.

Oncotarget. 2016 Jun 7;7(23):35293-301. doi: 10.18632/oncotarget.9182.

25.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
26.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
27.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
28.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

29.

[Multiple bladder diverticula caused by occipital horn syndrome].

Legros L, Revencu N, Nassogne MC, Wese FX, Feyaerts A.

Arch Pediatr. 2015 Nov;22(11):1147-50. doi: 10.1016/j.arcped.2015.07.017. Epub 2015 Sep 16. French.

PMID:
26386812
30.

Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.

Huet S, Dulucq S, Chauveau A, Ménard A, Chomel JC, Maisonneuve H, Legros L, Perrin MC, Ferrant E, Moreilhon C, Couturier MA, Sujobert P, Magaud JP, Ugo V, Chabane K, Raynaud S, Hayette S; GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes, French Molecular Biology Group in Hematology).

Genes Chromosomes Cancer. 2015 Oct;54(10):595-605. doi: 10.1002/gcc.22263. Epub 2015 Aug 7.

PMID:
26252834
31.

[Calreticulin mutations, a new diagnostic tool for the myeloproliferative disorders].

Legros L, Girodon F, Lanotto JC, Rey J, Ugo V; France intergroup on myeloproliferative syndromes (FIM).

Rev Med Interne. 2015 Dec;36(12):791-3. doi: 10.1016/j.revmed.2015.06.012. Epub 2015 Jul 13. French. No abstract available.

PMID:
26183578
32.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
33.

The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML.

Obba S, Hizir Z, Boyer L, Selimoglu-Buet D, Pfeifer A, Michel G, Hamouda MA, Gonçalvès D, Cerezo M, Marchetti S, Rocchi S, Droin N, Cluzeau T, Robert G, Luciano F, Robaye B, Foretz M, Viollet B, Legros L, Solary E, Auberger P, Jacquel A.

Autophagy. 2015;11(7):1114-29. doi: 10.1080/15548627.2015.1034406.

34.

The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells.

Mourgues L, Imbert V, Nebout M, Colosetti P, Neffati Z, Lagadec P, Verhoeyen E, Peng C, Duprez E, Legros L, Rochet N, Maguer-Satta V, Nicolini FE, Mary D, Peyron JF.

Leukemia. 2015 Oct;29(10):1993-2002. doi: 10.1038/leu.2015.112. Epub 2015 Apr 30.

PMID:
25925206
35.

Evidence of a target resistance to antivitamin K rodenticides in the roof rat Rattus rattus: identification and characterisation of a novel Y25F mutation in the Vkorc1 gene.

Goulois J, Chapuzet A, Lambert V, Chatron N, Tchertanov L, Legros L, Benoît E, Lattard V.

Pest Manag Sci. 2016 Mar;72(3):544-50. doi: 10.1002/ps.4020. Epub 2015 May 26.

PMID:
25847836
36.

Are nilotinib-associated vascular adverse events an under-estimated problem?

Stève-Dumont M, Baldin B, Legros L, Thyss A, Re D, Rocher F, Ajmia F, Spreux A, Drici MD.

Fundam Clin Pharmacol. 2015 Apr;29(2):204-8. doi: 10.1111/fcp.12102. Epub 2015 Mar 11.

PMID:
25619238
37.

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.

Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE.

Cancer. 2015 May 15;121(10):1637-44. doi: 10.1002/cncr.29240. Epub 2015 Jan 13.

38.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

39.

Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis.

Legros L, Bardou-Jacquet E, Latournerie M, Guillygomarc'h A, Turlin B, Le Lan C, Désille Y, Lainé F, Moirand R, Brissot P, Deugnier Y, Guyader D.

Liver Int. 2015 Jun;35(6):1731-8. doi: 10.1111/liv.12762. Epub 2015 Feb 4.

PMID:
25495562
40.

Long-term results of pneumatic dilatation for relapsing symptoms of achalasia after Heller myotomy.

Legros L, Ropert A, Brochard C, Bouguen G, Pagenault M, Siproudhis L, Bretagne JF.

Neurogastroenterol Motil. 2014 Sep;26(9):1248-55. doi: 10.1111/nmo.12380. Epub 2014 Jun 11.

PMID:
24916630
41.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J.

Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11.

42.

Regulatory T-cell depletion in donor lymphocyte infusions for haematological malignancies: long-term outcomes from a prospective study.

Maury S, Redjoul R, Cabanne L, Vigouroux S, Legros L, Cohen JL.

Br J Haematol. 2014 Aug;166(3):452-5. doi: 10.1111/bjh.12856. Epub 2014 Mar 25. No abstract available.

PMID:
24661112
43.

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C, Guilhot F, Hueber AO; French CML Group (FI-LMC).

Leuk Res. 2014 Jun;38(6):662-5. doi: 10.1016/j.leukres.2014.01.010. Epub 2014 Feb 1.

PMID:
24553365
44.

[Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the neuropathic manifestations in POEMS syndrome].

Gronier S, Delmont E, Legros L, Launay M, Jeandel PY, Fuzibet JG, Desnuelle C.

Rev Neurol (Paris). 2014 Jan;170(1):37-45. doi: 10.1016/j.neurol.2013.10.008. Epub 2014 Jan 8. French.

PMID:
24411685
45.

Imatinib treatment and Aβ42 in humans.

Olsson B, Legros L, Guilhot F, Strömberg K, Smith J, Livesey FJ, Wilson DH, Zetterberg H, Blennow K.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S374-80. doi: 10.1016/j.jalz.2013.08.283. Epub 2013 Dec 10.

PMID:
24331439
46.

Avulsion of the papilla of Vater managed using a rendezvous technique and extra-anatomic drainage.

Legros L, Quehen E, Bouguen G, Bretagne JF.

Endoscopy. 2013;45 Suppl 2 UCTN:E397-8. doi: 10.1055/s-0033-1344868. Epub 2013 Nov 27. No abstract available.

PMID:
24285068
47.

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L.

Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. No abstract available.

48.

Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F.

Cancer. 2013 Dec 15;119(24):4284-9. doi: 10.1002/cncr.28328. Epub 2013 Sep 16.

49.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S.

Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. No abstract available.

50.

The translocation t(4;14) can be present only in minor subclones in multiple myeloma.

Hébraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lodé L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H.

Clin Cancer Res. 2013 Sep 1;19(17):4634-7. doi: 10.1158/1078-0432.CCR-12-3866. Epub 2013 Jul 15.

Supplemental Content

Loading ...
Support Center